CompletedNot Applicable

Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19)

France809 participantsStarted 2020-03-01

Plain-language summary

Participants are healthcare workers and adult outpatients referred in a COVID-19 screening center. Patients-reported symptoms are collected, then participants underwent a simple olfactory test (CODA for Clinical Olfactory Dysfunction Assessment), prior to swabbing for SARS-CoV-2 diagnosis (RT-PCR). We aimed to evaluate the prevalence of smell and taste disorders, and to calculate the diagnostic value of patient-reported and clinically verified smell disorders in persons with suspected COVID-19.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Symptoms compatible with COVID-19 * Close exposure to a confirmed COVID-19 index case * Ambulatory (asymptomatic, or if symptomatic, did not require hospitalisation, thus with initial mild disease) Exclusion criteria: * known history of smell and taste disorders * testing inability (cognitive impairment, non native French speakers, test malingering) * testing contraindication (children, pregnancy, breastfeeding, specific allergies).

What they're measuring

Diagnostic values of anosmia and ageusia for COVID-19

Timeframe: at inclusion

Trial details

NCT IDNCT04407494

SponsorUniversity Hospital, Montpellier

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-04-01

View on ClinicalTrials.gov More COVID-19 trials